Peijia Medical Completes $100M Series C Financing，Providing Innovative Solutions for Cardiac Surgery

According to 36Kr.com, Peijia Medical, a provider of medical devices for heart valve disease treatment, announced the completion of a $100M Series C financing, with participation from an unknown international PE fund, Grand Flight Investment, China SDIC GaoXin Industrial Investment, and China Chengtong. Existing investors including MatrixPartners China and Lilly Asia Ventures also participated in the financing. Healthcare Capital served as the financial adviser.

Established in early 2012, Peijia Medical provides R&D and production of interventional medical products. The company covers an area of about 10000 square meters, within which laboratory and controlled environment room taking about 1800 square meters. 

Peijia Medical is dedicated to research, production, and sales of high-end medical devices for heart valve disease treatment. The core technical team came from famous international and domestic companies, with valuable experience in innovation, R&D, quality system, production and sales management. Its achievements include the successful launches of the first domestic heart drug-eluting stent and the first domestic intracranial embolization coil. 

Peijia Medical is developing its second generation of aortic valves, mitral and tricuspid valves, all of which are about to enter the clinical stage.

Grand Flight Investment, founded in mid-2016 and sponsored by Far East Horizon (HK.03360), is an emerging venture capital and private equity firm that manages both USD and RMB funds. The company focuses on discovering extraordinary companies in the early or expansion stage through our expertise in TMT, education, healthcare, enterprise service, and clean technology.

80% of portfolio companies of Grand Flight Investment finalized their next round financing within 2 years and 25% of them became unicorns. The investors include well-known domestic and international financial holding companies, insurance companies, and FOFs. 

China SDIC GaoXin Industrial Investment Corp., Ltd is a wholly-owned subsidiary of State Development & Investment Corp., Ltd. As an industry investment platform of SDIC, it is mainly engaged in the direct investment business as a holding company and equity fund business. The direct investment business as a holding company is mainly in the fields of advanced manufacturing and information technology, medicine, healthcare, and life science, environmental protection and new materials, etc. 

By the end of December 2018, the fund management scale of China SDIC GaoXin had reached 159.2 billion yuan.